Melbourne-based healthcare technology company Everlab has secured $15 million in seed funding to expand its artificial intelligence-powered preventive health platform across Australia and international markets. The funding round was led by global growth equity firm Left Lane Capital.
The startup operates a membership-based digital health platform that combines comprehensive diagnostic testing with AI-driven analysis and clinical oversight. Members gain year-round access to a range of diagnostic services including whole-body MRIs, blood testing, DEXA scans, VO2 max assessments, ECG monitoring, glucose tracking, CT coronary angiograms, and food journal analysis.
AI-Powered Clinical Workflow Automation
At the centre of Everlab’s offering lies a proprietary AI system designed to process both structured and unstructured health data from various sources, including laboratory results, medical imaging, and specialist reports. The platform integrates directly with national pathology and radiology systems rather than attempting to replace existing healthcare infrastructure.
“We took a more pragmatic and scalable approach, building on top of the existing systems rather than working around them” explained CEO and co-founder Marc Hermann. This interoperability strategy has enabled clinical continuity whilst maintaining regulatory compliance.
The AI system reportedly reduces the time required for clinicians to complete comprehensive preventive health reviews from approximately 10 hours to under 10 minutes. However, all diagnostic processes remain under the supervision of licensed doctors who apply clinical judgement before sharing results with members.
Tiered Membership Model Targets Accessibility
Everlab operates through a tiered membership structure designed to broaden access to preventive healthcare services. The flagship protocol membership costs $2,999 annually, whilst a more affordable option is available for $1,199 per year. Hermann indicated the company aims to reduce pricing further through continued automation of clinical workflows.
“We believe the realization of equitable preventive health lies in intelligent automation” Marc Hermann stated. The platform tailors diagnostic testing to individual risk profiles rather than employing broad screening approaches.
Clinical Outcomes and Early Detection
Since launch, Everlab reports processing more than one million biomarkers across its member base. According to the company, approximately 2.5% of members have received test results revealing potentially serious conditions, including gastrointestinal tumours, arterial blockages, and early-stage cancers.
A meta-analysis of members retested after six months showed that over one-third of modifiable biomarkers had improved, suggesting the platform’s preventive approach may be yielding measurable health outcomes.
The company emphasises its targeted approach to screening. “We’re not advocates of broad or indiscriminate screening” Marc Hermann noted, explaining that testing protocols are customized based on individual risk assessments rather than age-based generalizations.
Growth Trajectory and International Expansion
Everlab currently maintains a customer waitlist numbering in the tens of thousands and projects 20-fold growth for the current year. The company has recently expanded operations to multiple Australian cities and plans international market entry through 2026.
The fresh capital injection will support several growth initiatives, including expansion of the clinical network, growth of engineering and medical teams, and continued development of AI-powered infrastructure. The funding will also facilitate the company’s planned international expansion over the next two years.
“For us, sustainable growth means not just meeting demand, but doing so with reputable systems, scalable infrastructure, and proven clinical outcomes across diverse populations.” ~ Marc Hermann, co-founder and CEO.